APTOSE BIOSCIENCES INC.: 10-Q filed 2024-05-14
What APTOSE BIOSCIENCES INC. reported in its quarterly report filed 2024-05-14 (fiscal Q1 2024): 31 published measures, 64 facts as tagged in accession 0000950170-24-059768.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2024-05-14
- Fiscal period
- fiscal Q1 2024
- Accession
- 0000950170-24-059768 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All APTOSE BIOSCIENCES INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 12,796,000 | USD | |
| At 2023-12-31 | 12,989,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 12,659,000 | USD | |
| At 2023-12-31 | 15,890,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 137,000 | USD | |
| At 2023-12-31 | -2,901,000 | USD | |
| At 2023-03-31 | 25,993,000 | USD | |
| At 2022-12-31 | 37,741,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 7,346,000 | USD | |
| At 2023-12-31 | 9,252,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -9,640,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -13,676,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -11,763,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -11,302,000 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 11,847,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 50,000 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -1,991,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -2,960,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | -525,177,000 | USD | |
| At 2023-12-31 | -515,537,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 13,133,000 | shares | 91 |
| 2023-01-01 to 2023-03-31 | 6,171,000 | shares | 90 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 13,133,000 | shares | 91 |
| 2023-01-01 to 2023-03-31 | 6,171,000 | shares | 90 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -0.73 | USD/shares | 91 |
| 2023-01-01 to 2023-03-31 | -2.22 | USD/shares | 90 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -0.73 | USD/shares | 91 |
| 2023-01-01 to 2023-03-31 | -2.22 | USD/shares | 90 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 125,000 | USD | |
| At 2023-12-31 | 152,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 809,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 1,874,000 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 11,821,000 | USD | |
| At 2023-12-31 | 11,894,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 12,139,000 | USD | |
| At 2023-12-31 | 15,269,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 2,421,000 | USD | |
| At 2023-12-31 | 3,492,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 9,760,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 14,096,000 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 6,445,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 8,811,000 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 15,717,701 | shares | |
| At 2023-12-31 | 7,942,363 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 79,146,000 | USD | |
| At 2023-12-31 | 72,146,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | -4,317,000 | USD | |
| At 2023-12-31 | -4,316,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 850,000 | USD | |
| At 2023-12-31 | 943,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 919,000 | USD | |
| At 2023-12-31 | 1,015,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 9,319,000 | USD | |
| At 2023-12-31 | 8,829,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -9,641,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -13,672,000 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 3,315,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 5,285,000 | USD | 90 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 16,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 28,000 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 120,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 420,000 | USD | 90 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 115,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 128,000 | USD | 90 |
Inspect the source
- Entity
- APTOSE BIOSCIENCES INC. / CIK 0000882361
- Captured
- 2026-09-21T17:17:37.328Z
- SEC response SHA-256
7f77ad475e70835c104c58aaab4bd51268b09e41c459e013eaa3d9de6f814a73
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000882361.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))